{"resourceType": "Evidence", "meta": {"profile": ["http://hl7.org/fhir/uv/ebm/StructureDefinition/comparative-evidence"], "versionId": "6", "lastUpdated": "2025-12-08T13:42:49.209Z"}, "identifier": [{"type": {"coding": [{"system": "http://terminology.hl7.org/CodeSystem/v2-0203", "code": "ACSN", "display": "Accession ID"}], "text": "FEvIR Object Identifier"}, "system": "https://fevir.net/FOI", "value": "267244", "assigner": {"display": "Computable Publishing LLC"}}, {"type": {"text": "FEvIR Linking Identifier"}, "system": "https://fevir.net/FLI", "value": "NCT03421379-primaryOutcomeMeasure-0-OutcomeAnalysis-0-BetweenGroupAnalysis-OG000-OG001", "assigner": {"display": "Computable Publishing LLC"}}], "name": "NCT03421379_primaryOutcomeMeasure_0_OutcomeAnalysis_0_BetweenGroupAnalysis_OG000_OG001", "title": "Percentage of Participants Achieving Treatment Success During Controlled Insulin-Induced Hypoglycemia at Pre-dose up to 30 minutes post each glucagon administration Statistical Analysis for Glucagon Nasal Powder vs Glucagon Hydrochloride Solution in NCT03421379", "status": "active", "variableDefinition": [{"note": [{"text": "All randomized participant who completed both treatment visits and had evaluable treatment success data."}], "variableRole": "population", "intended": {"type": "Group", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "system": "https://fevir.net/FLI", "value": "NCT03421379 Eligibility Criteria", "assigner": {"display": "Computable Publishing LLC"}}, "reference": "Group/267225"}}, {"description": "Group Assignment: Glucagon Nasal Powder vs. Glucagon Hydrochloride Solution", "variableRole": "exposure", "comparatorCategory": "Glucagon Hydrochloride Solution", "observed": {"display": "Group Assignment: A single dose of 3 mg glucagon nasal powder was administered intranasally vs. A single dose of 1 mg glucagon hydrochloride solution was administered IM"}}, {"variableRole": "outcome", "observed": {"type": "EvidenceVariable", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "system": "https://fevir.net/FLI", "value": "NCT03421379-primaryOutcome-0", "assigner": {"display": "Computable Publishing LLC"}}, "display": "Percentage of Participants Achieving Treatment Success During Controlled Insulin-Induced Hypoglycemia at Pre-dose up to 30 minutes post each glucagon administration (NCT03421379)", "reference": "EvidenceVariable/267226"}}], "statistic": [{"note": [{"text": "Outcome Analysis NonInferiority Type: Non-Inferiority"}, {"text": "Outcome Analysis NonInferiority Comment: The pre-defined non-inferiority margin is (10%)"}], "statisticType": {"text": "Treatment Difference Wald's Method"}, "quantity": {"value": 0, "unit": "percentage of participants"}, "attributeEstimate": [{"note": [{"text": "CI Number of Sides: 2-Sided"}], "type": {"coding": [{"system": "http://terminology.hl7.org/CodeSystem/attribute-estimate-type", "code": "C53324", "display": "Confidence interval"}]}, "level": 0.95, "range": {"low": {"value": -1.47, "unit": "percentage of participants"}, "high": {"value": 1.47, "unit": "percentage of participants"}}}]}], "id": "267244", "url": "https://fevir.net/resources/Evidence/267244", "publisher": "Computable Publishing LLC", "copyright": "https://creativecommons.org/licenses/by-nc-sa/4.0/", "contact": [{"telecom": [{"system": "email", "value": "support@computablepublishing.com"}]}], "author": [{"name": "Computable Publishing\u00ae: ClinicalTrials.gov-to-FEvIR Converter"}], "citeAs": "Percentage of Participants Achieving Treatment Success During Controlled Insulin-Induced Hypoglycemia at Pre-dose up to 30 minutes post each glucagon administration Statistical Analysis for Glucagon Nasal Powder vs Glucagon Hydrochloride Solution in NCT03421379 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing\u00ae: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 267244. Revised 2025-12-08. Available at: https://fevir.net/resources/Evidence/267244. Computable resource at: https://fevir.net/resources/Evidence/267244#json.", "description": "This Evidence Resource is referenced in an example for the EBMonFHIR Implementation Guide."}